Shinkei Therapeutics LLC

Abeille Pharamaceuticals, Inc.

Suresh Borsadia

Kalpana J Patel

Gurpartap Singh Sachdeva

Hock Seng Tan

Krunal Raval

The invention is a dosing regimen for administering an aqueous composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and a second dose of amantadine hydrochloride by intravenous injection. The first dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose is administered after about four to six hours after the first dose is fully administered.

Amantadine hydrochloride for the treatment of traumatic brain injury

Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.

Tetrabenazine transdermal delivery device

A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Parenteral treatments involving aminoadamantane derivatives

Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

Dextromethorphan transdermal delivery device

Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of

Growing community of inventors

Plainsboro, NJ, United States of America

Suresh Borsadia